Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis
Launched by FARABI EYE HOSPITAL · Jul 30, 2019
Trial Information
Current as of May 11, 2025
Unknown status
Keywords
ClinConnect Summary
Diagnosed EKC patients will be devided into two groups,first group will undergo povidone-iodine 2% eye drop four times a day and the control group will be treated only by artificial tear drops,they will be examined 3 months later and evaluations and data collections for the final comparison will be done.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients suspected for viral conjunctivitis
- Exclusion Criteria:
- • Allergic to iodized materials
- • Age under 17
About Farabi Eye Hospital
Farabi Eye Hospital is a leading ophthalmic institution dedicated to advancing eye care through innovative research and clinical trials. Renowned for its expertise in diagnosing and treating various ocular conditions, the hospital combines state-of-the-art technology with a commitment to patient-centered care. By sponsoring clinical trials, Farabi Eye Hospital aims to explore new therapeutic approaches and improve treatment outcomes for patients suffering from eye disorders. Their rigorous research initiatives are designed to enhance understanding of ocular health and contribute to the global body of knowledge in ophthalmology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials